Circulating Tumor DNA Response In Urothelial Cancer

Cannot have received: antibody-drug conjugate (enfortumab, vedotin, other monomethyl auristatin E (MMAE)-based ADCs)

Previously received enfortumab, vedotin, or other monomethyl auristatin E (MMAE)-based ADCs.

Cannot have received: anti-PD-1 therapy

Exception: within 12 months

Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any malignancy, including earlier stage UC, defined as a PD-1 inhibitor or PD-L1 inhibitor within 12 months.

Cannot have received: anti-PD-L1 therapy

Exception: within 12 months

Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any malignancy, including earlier stage UC, defined as a PD-1 inhibitor or PD-L1 inhibitor within 12 months.

Cannot have received: systemic therapy for locally advanced or metastatic urothelial carcinoma

Exception: neoadjuvant chemotherapy with recurrence >12 months from completion of therapy permitted; adjuvant chemotherapy or ICPIs therapy following cystectomy with recurrence >12 months from completion of therapy permitted

Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions: Participants that received neoadjuvant chemotherapy with recurrence >12 months from completion of therapy are permitted. Participants that received adjuvant chemotherapy or ICPIs therapy following cystectomy with recurrence >12 months from completion of therapy are permitted.